Exclusive Cooperation Between ARTES and IPK - Clinical Trials Arena
Join Our Newsletter - Get important industry news and analysis sent to your inbox – sign up to our e-Newsletter here

Exclusive Cooperation Between ARTES and IPK

ARTES Biotechnology GmbH expands technology platform

Having achieved notable success with the Hansenula technology for years, the biotech company ARTES has now concluded an exclusive partnership with the internationally renowned Leibniz Institute of Plant Genetics and Crop Plant Research (IPK) in Gatersleben.

“The aim is a joint research and marketing of a new yeast expression technology,” explains Dr Melanie Dröttboom, in charge of Business Development at ARTES Biotechnology GmbH. “With the new collaboration we are able to expand our offer and we win an important academic research partner ,” says Dröttboom. Proffessor Gotthard Kunze, head of the department of Molecular Cell Biology, stands for the new agreement on behalf of the IPK Gatersleben. “This cooperation helps us to broaden and strengthen the research on the yeast Arxula adeninivorans ,” states Prof. Dr. Kunze. ARTES Biotechnology concentrates on applied research and on marketing.

ARTES Biotechnology GmbH is a service provider for production and optimisation of microbial recombinant protein strains, especially with the yeast organisms Hansenula and Arxula. The independent company, founded in 2002, holds worldwide patents and licences for these and further technology platforms. ARTES’ team is engaged in the production of recombinant proteins for clients in White Biotechnology (food and feed industry as well as fine chemical enzyme manufacturers industry) and in Red Biotechnology (pharmaceutical industry). The young biotech company has recently moved to a new 850m² facility with S1 laboratories. With its 16 employees ARTES is profitable and obtains through careful management an increase in turnover of 50 percent in the recent financial year.

More About This Company